Clinical trial · Interventional
Helping Young People With Testicular Cancer Using Virtual and Extended Reality
Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed. The project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up. TRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help. The ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AYA Cancer Survivors | — | UNRESOLVED | — |
| Survivor Patients | — | UNRESOLVED | — |
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
| Testis Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Digital tool using extended reality | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention arm (arm I)
- description
- participants will receive, in addition to their standard of care, an educational intervention via the digital tool for a period of 6 months, followed by an additional 12 months of follow-up.
- interventionNames
- Other: Digital tool using extended reality
- type
- NO_INTERVENTION
- label
- Control arm (arm C)
- description
- participants will receive their standard of care, without intervention, for a period of 6 months, followed by an additional 12 months of follow-up.
Primary outcomes (2)
- measure
- Pilot study: to determine the feasibility of implementing the XR digital tool in AYA survivors of testicular cancer
- timeFrame
- after 6 months of inclusion
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 15 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: 1. Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles). 2. Aged between 15 and 39 years at the time of study inclusion. 3. Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed. 4. Permitted treatment modalities: * Localised disease: orchiectomy with or without chemotherapy and/or radiotherapy. * Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed. 5. Willing and able to provide a valid and signed informed consent and/or assent, as appropriate. 6. ECOG performance status 0-2. 7. Patients accept to use personal smartphone 8. Patients able to read and understand the local language Exclusion Criteria: 1. Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours). 2. Non-germ cell TC. 3. Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4. 4. History of contralateral TC. 5. Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator. 6. Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy. 7. Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment. 8. AYA TC survivors with a "currently active" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years. 9. Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.
References
Publications (0)
Data not yet available